Search results
Showing 31 to 45 of 79 results for haematuria
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.
Show all sections
Sections for NG256
- Overview
- Information and support
- Diagnosis
- Managing oncocytomas and Bosniak 2F cysts
- Managing localised and locally advanced renal cell carcinoma
- Managing advanced renal cell carcinoma
- Managing renal cell carcinoma in people with a heritable renal cell carcinoma predisposition syndrome
- Terms used in this guideline
Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.
Fever in under 5s: assessment and initial management (NG143)
This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
This quality standard covers diagnosing and managing endometriosis in women and people, including those aged 17 and under. It describes high-quality care in priority areas for improvement.
Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)
We have moved interventional procedures guidance 709 to become HealthTech guidance 596. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Percutaneous radiofrequency ablation for renal cancer (HTG226)
Evidence-based recommendations on percutaneous radiofrequency ablation of renal cancer. This involves using heat produced through electrodes placed into the tumour to destroy the cancer cells.
View recommendations for HTG226Show all sections
Sections for HTG226
Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)
NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.